OvaScience Inc  

(Public, NASDAQ:OVAS)   Watch this stock  
Find more results for Mary McNeely�
+1.00 (8.89%)
Oct 9 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 11.17 - 12.36
52 week 7.90 - 55.69
Open 11.29
Vol / Avg. 484,804.00/890,491.00
Mkt cap 306.75M
P/E     -
Div/yield     -
EPS -2.62
Shares 27.27M
Beta     -
Inst. own 97%
Sep 29, 2015
OvaScience Inc Provides Update on Corporate Goal for AUGMENT Treatment - Conference Call - Webcast
Sep 9, 2015
OvaScience Inc at Rodman & Renshaw Global Investment Conference
Aug 25, 2015
OvaScience Inc Overview of AUGMENTSM Treatment Patient Experience - Presentation - Webcast
Aug 11, 2015
OvaScience Inc at Wedbush PacGrow Healthcare Conference
Aug 11, 2015
Q2 2015 OvaScience Inc Corporate Call - Webcast
Aug 10, 2015
Q2 2015 OvaScience Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -58300.00% -
Operating margin -57246.67% -
EBITD margin - -
Return on average assets -41.24% -87.56%
Return on average equity -43.06% -102.08%
Employees 52 -
CDP Score - -


215 1st St Ste 240
CAMBRIDGE, MA 02142-1293
United States - Map
+1-617-5002802 (Phone)
+1-302-6554620 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


OvaScience, Inc. is a global fertility company. The Company is focused on the discovery, development and commercialization of new fertility treatments based on egg precursor or EggPC cells, which are immature egg cells found in the protective outer layer of a woman's own ovaries. With the Company's AUGMENT treatment, energy-producing mitochondria from a patient's own EggPC cells are added to the patient's mature eggs during the In vitro fertilization (IVF) process to supplement the existing mitochondria. Its OvaPrime treatment is designed to replenish a woman's egg reserve by transferring a patient's EggPC cells from the protective ovarian lining back into the patient's own ovaries where they may mature into fertilizable eggs during the IVF process. The OvaTure treatment seeks to mature a woman's own EggPC cells into eggs outside her body. The OvaXon is a joint venture with Intrexon Corporation to create new applications to prevent inherited diseases for human and animal health.

Officers and directors

Richard H. Aldrich Independent Chairman of the Board
Age: 60
Bio & Compensation  - Reuters
Arthur Tzianabos Ph.D. President, Chief Scientific Officer
Age: 52
Bio & Compensation  - Reuters
Michelle Dipp M.D., Ph.D. Chief Executive Officer, Director
Age: 38
Bio & Compensation  - Reuters
Theresa McNeely Executive Vice President, Chief Communications Officer
Age: 51
Bio & Compensation  - Reuters
Jeffrey E. Young Chief Financial Officer, Treasurer
Age: 41
Bio & Compensation  - Reuters
David P. Harding Chief Commercial Officer
Age: 49
Bio & Compensation  - Reuters
Ravi Mehrotra Ph.D. Chief Corporate Development Officer
Bio & Compensation  - Reuters
John P. Howe III, M.D. Director
Age: 65
Bio & Compensation  - Reuters
John E. Sexton Ph.D. Director
Bio & Compensation  - Reuters
Jeffrey D. Capello Independent Director
Age: 50
Bio & Compensation  - Reuters